Kala Pharmaceuticals (KALA)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	49.20 mm	49.20 mm	49.20 mm	49.20 mm	49.20 mm	49.20 mm
Cash burn (monthly)	(no burn)	4.50 k	3.33 mm	3.36 mm	49.33 k	1.80 mm
Cash used (since last report)	n/a	12.67 k	9.38 mm	9.46 mm	138.93 k	5.08 mm
Cash remaining	n/a	49.19 mm	39.83 mm	39.74 mm	49.06 mm	44.12 mm
Runway (months of cash)	n/a	10931.0	12.0	11.8	994.5	24.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

KALA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	20	30	-33.3%
Opened positions	6	22	-72.7%
Closed positions	16	1	+1500.0%
Increased positions	3	0	NEW
Reduced positions	1	1	–

13F shares	Current	Prev Q	Change
Total value	8.51 bn	1.54 bn	+454.1%
Total shares	17.86 mm	16.43 mm	+8.8%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Blumenkranz Mark S.	5.14 mm	$10.80 mm	0.0%
Lagunita	5.14 mm	$10.80 mm	0.0%
Lagunita Biosciences	5.14 mm	$10.80 mm	0.0%
Baker Bros. Advisors	891.34 k	$6.32 bn	NEW
Polaris Venture Partners V	598.62 k	$2.21 mm	0.0%
SR One Capital Management	445.64 k	$3.16 mm	NEW
Ubs Oconnor	147.55 k	$1.05 bn	+103.4%
Millennium Management	142.28 k	$1.01 bn	NEW
Integrated Core Strategies	132.67 k	$0.00	0.0%
Longitude Capital Partners II	57.54 k	$884.00 k	0.0%

Largest transactions	Shares	Bought/sold	Change
Baker Bros. Advisors	891.34 k	+891.34 k	NEW
SR One Capital Management	445.64 k	+445.64 k	NEW
Millennium Management	142.28 k	+142.28 k	NEW
Ubs Oconnor	147.55 k	+75.00 k	+103.4%
Vanguard	0.00	-41.98 k	EXIT
BLK BlackRock	0.00	-27.18 k	EXIT
Board of Trustees of The Leland Stanford Junior University	0.00	-21.13 k	EXIT
Geode Capital Management	0.00	-18.15 k	EXIT
Sassicaia Capital Advisers	12.00 k	+12.00 k	NEW
Renaissance Technologies	0.00	-11.40 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

KALA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
26 Jun 24	Darius Kharabi	Common Stock	Sell	Dispose S	No	Yes	4.75	5,158	24.50 k	59,728
26 Jun 24	Bazemore Todd	Common Stock	Sell	Dispose S	No	Yes	4.75	4,653	22.10 k	83,040
26 Jun 24	Reumuth Mary	Common Stock	Sell	Dispose S	No	Yes	4.75	4,163	19.77 k	60,187
26 Jun 24	Brazzell Romulus K	Common Stock	Sell	Dispose S	No	Yes	4.75	5,489	26.07 k	83,982

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Kala Bio, Maintains $15 Price Target

15 Nov 24

HC Wainwright & Co. analyst Yi Chen reiterates Kala Bio (NASDAQ:KALA) with a Buy and maintains $15 price target.

Press releases

From Benzinga Pro

KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 Nov 24

-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline results expected in 2Q 2025 -- -- Initiated five clinical trial sites for the CHASE trial in